Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling-Reference-Cited by-同舟云学术

Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling

Published:2008-01-29 Issue:3 Volume:24 Page:753-768
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Ballal Rahul D.¹,Botteman Marc F.²,Foley Isaac²,Stephens Jennifer M.²,Wilke Caitlyn T.³,Joshi Ashish V.⁴

Affiliation:

1. Georgetown University, Washington, DC, USA

2. Health Economics, Pharmerit North America LLC, Bethesda, MD, USA

3. Novo Nordisk Health Outcomes, Novo Nordisk Inc., Princeton, NJ, USA; and University of Illinois at Chicago, Center for Pharmacoeconomic Research, Chicago, IL, USA

4. Novo Nordisk Inc., Princeton, NJ, USA

Publisher

Informa Healthcare

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1185/030079908X273048

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany;PharmacoEconomics - Open;2024-03-23

2. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting;BMC Medical Research Methodology;2022-08-05

3. Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A;HemaSphere;2022-01-28

4. Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea;Haemophilia;2020-09-07

5. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A;Journal of Medical Economics;2020-02-13